Brief: Revive Therapeutics Applies To FDA For Orphan Drug Designation Of Cannabidiol For Treatment Of Liver Transplantation
22/08/2018 12:16
Aug 22 (Reuters) - Revive Therapeutics Ltd RVV.V :
* REVIVE THERAPEUTICS APPLIES TO FDA FOR ORPHAN DRUG
DESIGNATION
OF CANNABIDIOL FOR TREATMENT OF LIVER TRANSPLANTATION
Source text for Eikon: ID:nGNX5MGyXp
Further company coverage: RVV.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure